Log in
Enquire now
Auransa

Auransa

A biotechnology company applying AI and genomics to precision medicine to address patient subpopulations that have unmet needs. Their pipeline of drug candidates address cancer, neurology, inflammation, infectious disease and metabolic disease. It is located in Palo Alto, California and was founded in 2014.

OverviewStructured DataIssuesContributors

Contents

auransa.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Machine learning
Machine learning
Artificial Intelligence (AI)
Artificial Intelligence (AI)
Precision for Medicine
Precision for Medicine
Software development
Software development
Therapeutics
Therapeutics
Drug development
Drug development
0
Technology
Technology
...
Location
San Francisco
San Francisco
Palo Alto, California
Palo Alto, California
B2X
B2B
B2B
CEO
‌
Pek Lum, PhD
Founder
‌
Pek Lum, PhD
0
‌
Viwat Visuthikraisee, PhD
Pitchbook URL
pitchbook.com/profiles...155785-51
Legal Name
Auransa, Inc.
Date Incorporated
2014
Number of Employees (Ranges)
11 – 50
Email Address
info@auransa.com
Full Address
550 Hamilton Ave, Palo Alto, California US
Investors
Lux Capital Management
Lux Capital Management
AME Cloud Ventures
AME Cloud Ventures
DCVC Bio
DCVC Bio
11.2 Capital
11.2 Capital
Harmonix
Harmonix
Founded Date
2019
0
Glassdoor ID
3157166
Also Known As
CapellaBio
Patents Assigned (Count)
1
COO
‌
Viwat Visuthikraisee, PhD
Country
United States
United States

Other attributes

Company Operating Status
Active
Partner Organizations
Roche
Roche
Taiho Pharmaceutical
Taiho Pharmaceutical
Stem Cell Theranostics
Stem Cell Theranostics
UCLA Health (company)
UCLA Health (company)
Takeda Pharmaceutical Company
Takeda Pharmaceutical Company

Auransa is a California-based artificial technology company specializing in precise pharmaceuticals. At the core of its platform, the company predicts treatments, initiates drug discovery and research, identify patients who could use the pharmaceutical in trials, and monitors said patients.

Product

The company has developed multiple products, such as the SMarTR Engine, and CTSeek Liquid Biopsy Technology. The SMarTR Engine uses machine learning, advanced analytics and mathematics in an AI framework to predict disease subtypes. Auransa has discovered patient subtyes for 30 disease and is utilizing the SMarTR Engine to find more.

The CTSeek is used for clinical trials and is a liquid biopsy diagnostic technology which generates insights from molecular data to understand the biology of disease and patient subtypes. The information is combined with in-house drug discovery and development for identification of novel compounds to address unmet medical needs for disease subtypes that are clinically meaningful.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia

Auransa

https://www.globenewswire.com/news-release/2018/12/19/1669377/0/en/Auransa-Enters-into-Exclusive-Licensing-Agreement-with-China-Oncology-Focus-Limited-an-Affiliate-of-Lee-s-Pharmaceutical-Holdings-for-Rights-to-AU018-in-Greater-China-and-Southeast.html

Web

December 19, 2018

https://www.linkedin.com/company/auransa-inc

Web

References

Find more companies like Auransa

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.